Log In
Print
BCIQ
Print
Print this Print this
 

ocrelizumab (R1594, RG1594)

Also known as: Anti-CD20

  Manage Alerts
Collapse Summary General Information
Company Biogen Idec Inc.
DescriptionSecond-generation humanized mAb against CD20
Molecular Target CD20
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat primary progressive multiple sclerosis (PPMS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation

Partner

Genentech Inc.; Roche


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today